SCHEMBL6716641

SCHEMBL6716641

O=S(=O)(Nc1cccc(C2=NCCc3ccc(F)cc32)c1)c1ccc(C(F)(F)F)cc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PFKFB3 Q16875 1/20 0.47
CDK1 P06493 1/20 0.46
CCNB1 P14635 1/20 0.46
CCNA2 P20248 1/20 0.46
CCND1 P24385 1/20 0.46
CDK2 P24941 1/20 0.46
CDK7 P50613 1/20 0.46
CCNH P51946 1/20 0.46
CCNA1 P78396 1/20 0.46
CDK6 Q00534 1/20 0.46
CYP3A4 P08684 1/20 0.45
PPARG P37231 1/20 0.45
LMNA P02545 2/20 0.44
TP53 P04637 2/20 0.42
MAPK10 P53779 1/20 0.41
MCL1 Q07820 3/20 0.41
PFKFB4 Q16877 1/20 0.41
KIF11 P52732 1/20 0.39
SGK1 O00141 2/20 0.38
PRF1 P14222 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6718694 0.94 PFKFB3 (0.48) PFKFB3CDK1CCNB1CCNA2CCND1
SCHEMBL6717790 0.92 CDK1 (0.47) PFKFB3CDK1CCNB1CCNA2CCND1
SCHEMBL6717907 0.92 PFKFB3 (0.55) PFKFB3LMNATP53MAPK10SGK1
SCHEMBL6716447 0.91 CDK1 (0.49) PFKFB3CDK1CCNB1CCNA2CCND1
SCHEMBL6715037 0.90 SGK1 (0.45) PFKFB3CDK1CCNB1CCNA2CCND1
SCHEMBL6714983 0.90 CDK1 (0.50) PFKFB3CDK1CCNB1CCNA2CCND1
SCHEMBL6720522 0.88 CDK1 (0.47) PFKFB3CDK1CCNB1CCNA2CCND1
SCHEMBL6720387 0.87 PFKFB3 (0.52) PFKFB3CYP3A4PPARGLMNATP53
SCHEMBL6720563 0.86 PFKFB3 (0.55) PFKFB3LMNATP53MAPK10SGK1
SCHEMBL6718324 0.85 TSHR (0.47) PFKFB3CDK1CCNB1CCNA2CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6818651-B2 ANTIINFLAMMATORY, ANTIASTHMATIC, SKIN, AND AUTOIMMUNE DISORDERS; CROHN*S DISEASE, ULCERATIVE COLITIS, CONJUCTIVITIS, MULTIPLE SCLEROSIS, AND RHEUMATOID ARTHRITIS; CHRONIC OBSTRUCTIVE PULMONARY DISEASE ALTANA PHARMA AG (DE) 2004-11-16 US disclosed
US-20040044212-A1 (Dihydro) Isoquinoline derivatives as phosphodiesterase inhibitors ALTANA PHARMA AG (DE) 2004-03-04 US disclosed
EP-1337515-A1 (DIHYDRO)ISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 2003-08-27 EP disclosed
WO-2002040450-A1 (DIHYDRO)ISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS ALTANA PHARMA AG (DE) 2002-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044212-A1 (Dihydro) Isoquinoline derivatives as phosphodiesterase inhibitors PDE7B, PDE3B, PDE3A PFKFB3 2298/4885CDK1 2926/4885CCNB1 4052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.